Some tau species are transferred between neurons but remain non-pathogenic because they stay trapped in degradative endosomal routes. Seed-competent tau either escapes into cytosol or traffics through compartments that expose it to soluble tau substrate.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["RAB7A"] --> B["Late endosome maturation"]
A --> C["Endosomal trafficking regulation"]
B --> D["Lysosomal fusion and delivery"]
C --> E{"Endosomal membrane integrity"}
E --> F["Endosomal escape"]
E --> G["Endosomal retention"]
F --> H["Cytosolic tau exposure"]
G --> I["Delivery to lysosome"]
I --> J["Lysosomal degradation"]
J --> K["Non-pathogenic tau clearance"]
H --> L["Seed-competent tau formation"]
L --> M["Tau aggregation and propagation"]
M --> N["Neuronal dysfunction"]
style A fill:#4fc3f7
style B fill:#4fc3f7
style C fill:#4fc3f7
style D fill:#4fc3f7
style I fill:#4fc3f7
style J fill:#4fc3f7
style E fill:#ffd54f
style F fill:#ef5350
style G fill:#81c784
style H fill:#ef5350
style K fill:#81c784
style L fill:#ef5350
style M fill:#ef5350
style N fill:#ef5350
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 56%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
MECH 2CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
No claim
Supporting
MECH
Exosome and end…
-
-
-
-
-
No claim
Opposing
MECH
-
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
No claim
Exosome and endolysosomal tau-transfer literature
✗ Opposing Evidence
1
No claim
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Seed-competent tau is likely defined by a compact beta-rich conformer exposing repeat-domain surfaces, a permissive PTM barcode, and packaging into vesicles or synaptic compartments that protect it from degradation during transfer.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Uptake is not seeding. The decisive experiment must compare matched tau species that enter neurons equally but differ in templating kinetics, persistence, and downstream neurotoxicity.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Clinically, the best product concept is a conformation- or PTM-selective antibody paired with CSF seed amplification or tau-PET enrichment. Broad tau lowering risks interfering with normal microtubule biology.
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Ranked synthesis: conformer exposure is primary, PTM barcode is the strongest modulator, and vesicle context explains why some transferable tau remains non-pathogenic.